The FDA gave the green light to Novartis’s tisagenlecleucel for the treatment of acute
lymphoblastic leukaemia (ALL), marking a historic approval for a first-in-modality chimeric
antigen receptor (CAR) T cell therapy…

Fonte: Nature Reviews Drug Discovery | Published online 29 Sep 2017

Para acessar a publicação na íntegra clique  aqui